Compagnie Lombard Odier SCmA Buys 56,371 Shares of Thermo Fisher Scientific Inc. (NYSE:TMO)

Compagnie Lombard Odier SCmA lifted its position in Thermo Fisher Scientific Inc. (NYSE:TMO) by 29.1% during the first quarter, HoldingsChannel.com reports. The institutional investor owned 250,267 shares of the medical research company’s stock after purchasing an additional 56,371 shares during the period. Thermo Fisher Scientific accounts for approximately 1.5% of Compagnie Lombard Odier SCmA’s investment portfolio, making the stock its 16th largest holding. Compagnie Lombard Odier SCmA’s holdings in Thermo Fisher Scientific were worth $124,533,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Other large investors also recently modified their holdings of the company. Bernard Wealth Management Corp. purchased a new stake in shares of Thermo Fisher Scientific during the 4th quarter valued at about $25,000. FPC Investment Advisory Inc. purchased a new stake in Thermo Fisher Scientific during the fourth quarter valued at approximately $28,000. Pillar Financial Advisors LLC purchased a new position in shares of Thermo Fisher Scientific during the 4th quarter worth $29,000. Ameriflex Group Inc. purchased a new stake in shares of Thermo Fisher Scientific in the 4th quarter worth $30,000. Finally, Noble Wealth Management PBC purchased a new position in Thermo Fisher Scientific during the fourth quarter valued at $35,000. Institutional investors own 89.23% of the company’s stock.

Thermo Fisher Scientific Trading Up 0.2%

TMO opened at $415.25 on Thursday. The company has a debt-to-equity ratio of 0.59, a current ratio of 1.66 and a quick ratio of 1.29. The company’s 50 day simple moving average is $417.57 and its two-hundred day simple moving average is $493.84. The firm has a market capitalization of $156.76 billion, a price-to-earnings ratio of 25.12, a price-to-earnings-growth ratio of 2.99 and a beta of 0.78. Thermo Fisher Scientific Inc. has a 1-year low of $390.50 and a 1-year high of $627.88.

Thermo Fisher Scientific (NYSE:TMO) last issued its earnings results on Wednesday, April 23rd. The medical research company reported $5.15 EPS for the quarter, topping analysts’ consensus estimates of $5.10 by $0.05. Thermo Fisher Scientific had a net margin of 14.78% and a return on equity of 17.51%. The company had revenue of $10.36 billion for the quarter, compared to the consensus estimate of $10.23 billion. During the same period in the previous year, the firm earned $5.11 earnings per share. Thermo Fisher Scientific’s quarterly revenue was up .2% compared to the same quarter last year. Analysts expect that Thermo Fisher Scientific Inc. will post 23.28 EPS for the current fiscal year.

Thermo Fisher Scientific Announces Dividend

The firm also recently announced a quarterly dividend, which will be paid on Tuesday, July 15th. Shareholders of record on Friday, June 13th will be paid a dividend of $0.43 per share. The ex-dividend date of this dividend is Friday, June 13th. This represents a $1.72 annualized dividend and a yield of 0.41%. Thermo Fisher Scientific’s dividend payout ratio (DPR) is 10.09%.

Insider Activity

In other Thermo Fisher Scientific news, EVP Gianluca Pettiti sold 300 shares of the company’s stock in a transaction dated Monday, April 28th. The shares were sold at an average price of $429.93, for a total value of $128,979.00. Following the transaction, the executive vice president now directly owns 23,167 shares in the company, valued at approximately $9,960,188.31. This represents a 1.28% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Corporate insiders own 0.33% of the company’s stock.

Analysts Set New Price Targets

A number of analysts have commented on TMO shares. Citigroup reduced their price target on Thermo Fisher Scientific from $650.00 to $570.00 and set a “neutral” rating for the company in a research report on Tuesday, March 4th. Royal Bank of Canada reduced their target price on shares of Thermo Fisher Scientific from $651.00 to $637.00 and set an “outperform” rating for the company in a report on Thursday, April 24th. The Goldman Sachs Group set a $610.00 price target on shares of Thermo Fisher Scientific and gave the company a “buy” rating in a report on Wednesday, April 23rd. Stifel Nicolaus decreased their price objective on shares of Thermo Fisher Scientific from $665.00 to $620.00 and set a “buy” rating on the stock in a research report on Thursday, April 24th. Finally, UBS Group lowered their price target on Thermo Fisher Scientific from $715.00 to $500.00 and set a “buy” rating on the stock in a report on Thursday, April 24th. Four analysts have rated the stock with a hold rating and seventeen have issued a buy rating to the company. According to MarketBeat, the company has a consensus rating of “Moderate Buy” and an average target price of $605.30.

Thermo Fisher Scientific Company Profile

Thermo Fisher Scientific Inc provides life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services in the North America, Europe, Asia-Pacific, and internationally. The company's Life Sciences Solutions segment offers reagents, instruments, and consumables for biological and medical research, discovery, and production of drugs and vaccines, as well as diagnosis of infections and diseases; and solutions include biosciences, genetic sciences, and bio production to pharmaceutical, biotechnology, agricultural, clinical, healthcare, academic, and government markets.